Reduction of isoprenaline-induced myocardial TGF-β1 expression and fibrosis in osthole-treated mice

Toxicology and Applied Pharmacology

Volumn 256, Issue 2, 2011, Pages 168-173

  Chen, Rong ^a,b   Xue, Jie ^a   Xie, Mei Lin ^a  

^a SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cnidium monnieri (L.) Cusson; Myocardial fibrosis; Nuclear factor B; Osthole; Peroxisome proliferator activated receptor ; Transforming growth factor 1

Indexed keywords

CAPTOPRIL; COLLAGEN; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPRENALINE; MESSENGER RNA; OSTHOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; HEART; HEART MUSCLE FIBROSIS; HEART WEIGHT; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; CARDIOTONIC AGENTS; COLLAGEN; COUMARINS; FIBROSIS; GENE EXPRESSION REGULATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HEART; ISOPROTERENOL; MALE; MICE; MYOCARDIUM; PPAR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1;

CNIDIUM MONNIERI; MUS;

EID: 80053130410     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.08.005     Document Type: Article

References (38)

1. Barger P.M., Kelly D.P. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 2000, 10:238-245.
2. Blanquart C., Barbier O., Fruchart J.C., Staels B., Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 2003, 85:267-273.
3. Brooks W.W., Conrad C.H. Myocardial fibrosis in transforming growth factor β1 heterozygous mice. J. Mol. Cell. Cardiol. 2000, 32:187-195.
4. Brouri F., Hanoun N., Mediani O., Saurini F., Hamon M., Vanhoutte P.M., Lechat P. Blockade of β1-and desensitization of β2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur. J. Pharmacol. 2004, 485:227-234.
5. Chang F., Jaber L.A., Berlie H.D., O'Connell M.B. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 2007, 41:973-983.
6. Chen R., Xie M.L., Zhou J. Experimental study of osthole on inhibition of thrombosis and platelet aggregation. Chin. Pharmacol. Bull. 2005, 21:440-443.
7. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 2001, 169:453-459.
8. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
9. Diep Q., Benkiran K., Amiri F., Cohn J.S., Endemann D., Schiffrin E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J. Mol. Cell. Cardiol. 2004, 36:295-304.
10. Dostal D.E., Booz G.W., Baker K.M. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and β-adrenergic stimulation. Basic Res. Cardiol. 2000, 95:485-490.
11. Galderisi M., de Divitiis O. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 2008, 51:523-531.
12. Hiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., Ishibashi M., Kubota T., Egashira K., Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 106:3126-3132.
13. Hou X.H., Cao B., Liu H.Q., Wang Y.Z., Bai S.F., Chen H. Effects of osthole on apoptosis and TGF-beta1 of hypertrophic scar fibroblasts. J. Asian Nat. Prod. Res. 2009, 11:663-669.
14. Kim D.J., Murray I.A., Burns A.M., Gonzalez F.J., Perdew G.H., Peters J.M. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem. 2005, 280:9519-9527.
15. Ko F.N., Wu T.S., Liou M.J., Huang T.F., Teng C.M. Vasorelaxation of rat thoracic aorta caused by osthole isolated from Angelica pubescens. Eur. J. Pharmacol. 1992, 219:29-34.
16. Kumar A., Meyerrose G., Sood V., Roongsritong C. Diastolic heart failure in the elderly and the potential role of aldosterone antagonists. Drugs Aging 2006, 23:229-308.
17. Leask A., Abraham D.J. TGF-beta signaling and the fibrotic response. FASEB J. 2004, 18:816-827.
18. Li M., Zhang J., Chen Y., Wang Y.Q. Danshen inhibiting isoproterenol induced cardiac hypertrophy and fibrosis in mice and its mechanisms. J. China. Pharm. Univ. 2003, 34:565-568.
19. Lian Q.S. Progress in study of chemical constituents and pharmacological effects of the fruit of Cnidium monnieri. Chin. Med. Mater. 2003, 26:141-144.
20. Liang H.J., Suk F.M., Wang C.K., Hung L.F., Liu D.Z., Chen N.Q., Chen Y.C., Chang C.C., Liang Y.C. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mouse. Chem. Biol. Interact. 2009, 181:309-315.
21. Liao P.C., Chien S.C., Ho C.L., Wang E.C., Lee S.C., Kuo Y.H., Jeyashoke N., Chen J., Dong W.C., Chao L.K., Hua K.F. Osthole regulates inflammatory mediator expression through modulating NF-κB, mitogen-activated protein kinases, protein kinase C, and reactive oxygen species. J. Agric. Food Chem. 2010, 58:10445-10451.
22. Liu J.X., Zhang W.P., Zhou L., Wang X.R., Lian Q.S. Anti-inflammatory effect and mechanism of osthole in rats. J. Chin. Med. Mater. 2005, 28:1002-1006.
23. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-263.
24. Nissen S.E., Wolski K., Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. Am. Med. Assoc. 2005, 294:2581-2586.
25. Ogawa H., Sasai N., Kamisako T., Baba K. Effects of osthol on blood pressure and lipid metabolism in stroke-prone spontaneously hypertensive rats. J. Ethnopharmacol. 2007, 112:26-31.
26. Ogata M., Touyz R.M., Viel E.C., Paradis P., Amiri F., Diep Q.N., Schiffrin E.L. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003, 42:737-743.
27. Ogata T., Miyauchi T., Sakai S., Irukayama T.Y., Goto K., Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin. Sci. 2002, 103:284S-288S.
28. Ogata T., Miyauchi T., Sakai S., Takanashi M., Irukayama T.Y., Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol. 2004, 43:1481-1488.
29. Okamoto T., Kawasaki T., Hino O. Osthole prevents anti-fas antibody-induced hepatitis in mouse by affecting the caspase-3-mediated apoptotic pathway. Biochem. Pharmacol. 2003, 65:677-681.
30. Parra J.L., Reddy K.R. Hepatotoxicity of hypolipidemic drugs. Clin. Liver Dis. 2003, 7:415-433.
31. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Therapeut. 2009, 123:255-278.
32. Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovas. Res. 2004, 63:423-432.
33. Song F., Xie M.L., Zhu L.J., Zhang K.P., Xue J., Gu Z.L. Regulatory mechanism of osthole on lipid metabolism in alcohol-induced fatty liver rats. Chin. Pharmacol. Bull. 2008, 24:979-980.
34. Sun F., Xie M.L., Xue J., Wang H.B. Osthol regulates hepatic PPARα-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine 2010, 17:669-673.
35. Triggle D.J. Calcium channel antagonists: clinical uses-past, present and future. Biochem. Pharmacol. 2007, 74:1-9.
36. Zandbergen F., Mandard S., Escher P., Tan N.S., Patsouris D., Jatkoe T., Caro S.R., Madore S., Wahli W., Tafuri S., Müller M., Kersten S. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem. J. 2005, 392:313-324.
37. Zhang R.Y., Wang L.F., Zhang L., Meng X.N., Li S.J., Wang W.R. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats. Chinese Med. J. 2006, 119:649-655.
38. Zhang Y., Xie M.L., Xue J., Gu Z.L. Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPAR α/γ in fat milk-induced fatty liver rats. J. Asian Nat. Prod. Res. 2008, 10:797-802.